Systemic autoimmune disease as a consequence of defective lymphocyte death

Current Opinion in Immunology

Volumn 9, Issue 6, 1997, Pages 826-830

  Hünig, Thomas ^a   Schimpl, Anneliese ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; FAS ANTIGEN; GENE PRODUCT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DEATH; CLONE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; REVIEW;

EID: 0344404151     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80185-9     Document Type: Review

References (59)

1. Watanabe-Fukunaga R, Brennan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
2. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copetand NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994, 76:969-976.
3. Lynch DH, Watson M, Alderson MR, Baum PR, Miller RE, Tough T, Gibson M, Davis-Smith T, Smith CA, Hunter K et al.: The mouse Fas-ligand gene is mutated in gld mice and is part of the TNF gene cluster. Immunity 1994, 1:131-136.
4. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946.
5. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268:1347-1349.
6. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity [see comments]. N Engl J Med 1996, 335:1643-1649.
7. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD: Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996, 98:1107-1113. Identification of a gld-like mutation in a patient with lymphoproliferative disorder. This was the first case described for CD95L deficiency.
8. Dianzani U, Bragardo M, DiFranco D, Alliaudi C, Scagni P, Buonfiglio D, Redoglia V, Bonissoni S, Correra A, Dianzani I et al.: Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood 1997, 89:2871-2879. This paper provides the starting point for the identification of genes, distinct from either CD95 or its ligand, which are part of or regulate the CD95-me-diated apoptotic pathway.
9. Nagata S: Apoptosis by death factor. Cell 1997, 88:355-365.
10. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer J-L, Schröter M, Burns K, Mattman C et al.: Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
11. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R et al.: FLICE, a novel FADD homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signalling complex. Cell 1996, 85:817-827.
12. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, Fleisher TA, Lim MS, Jaffe ES, Puck JM et al.: Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997, 89:1341-1348. A careful and extensive description of eight patients with a heterozygous CD95 mutation.
13. Izui S, Kelley VE, Masuda K, Yoshida H, Roths JB, Murphy ED: Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 1984, 133:227-233.
14. Warren RW, Caster SA, Roths JB, Murphy ED, Pisetsky DS: The influence of the lpr gene on B cell activation: differential antibody expression in lpr congenic mouse strains. Clin Immunol Immunopathol 1984, 31:65-77.
15. Tamura A, Katsumata M, Greene MI, Yui K: Inhibition of apoptosis and augmentation of lymphoproliferation in bel- 2 transgenic Fas/Fas ligand-defective mice. Cell Immunol 1996, 168:220-228.
16. Strasser A, Harris AW, Huang DC, Krammer PH, Cory S: Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995, 14:6136-6147.
17. Reap EA, Felix NJ, Wolthusen PA, Kotzin BL, Cohen PL, Eisenberg RA: bcl-2 transgenic Lpr mice show profound enhancement of lymphadenopathy. J Immunol 1995, 155:5455-5462.
18. Sobel ES, Katagiri T, Katagiri K, Morris SC, Cohen PL, Eisenberg RA: An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med 1991, 173:1441-1449.
19. Katagiri T, Azuma S, Toyoda Y, Mori S, Kano K, Cohen PL, Eisenberg RA: Tetraparental mice reveal complex cellular interactions of the mutant, autoimmunity-inducing lpr gene. J Immunol 1992, 148:430-438.
20. Nemazee D, Guiet C, Buerki K, Marshak-Rothstein A: B lymphocytes from the autoimmune-prone mouse strain MLR/lpr manifest an intrinsic defect in tetraparental MRL/lpr in equilibrium DBA/2 chimeras. J Immunol 1991, 147:2536-2539.
21. Rathmell JC, Cooke MP, Ho WY, Grein J, Townsend SE, Davis MM, Goodnow CC: CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 1995, 376:181-184.
22. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC: Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996, 87:319-329. An elegant paper utilizing the well-established hen egg lysozyme (HEL)/anti-HEL B cell receptor (BCR) transgenic system to demonstrate the interplay between the BCR, CD40 and CD95 in deciding the death or survival of B cells in self versus nonself discrimination.
23. Elkon KB, Marshak-Rothstein A: B cells in systemic autoimmune disease: recent insights from Fas-deficient mice and men. Curr Opin Immunol 1996, 8:852-859.
24. Su X, Zhou T, Wang Z, Yang P, Jope RS, Mountz JD: Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 1995, 2:353-362.
25. Anderson CC, Cairns E, Rudofsky UH, Sinclair NR: Defective antigen-receptor-mediated regulation of immunoglobulin production in B cells from autoimmune strains of mice. Cell Immunol 1995, 164:141-149.
26. Koh DR, Ho A, Rahemtulla A, Fung Leung WP, Griesser H, Mak TW: Murine lupus in MRL/lpr mice lacking CD4 or CDS T cells. Eur J Immunol 1995, 25:2558-2562.
27. Peng SL, Madaio MR Hughes DP, Crispe IN, Owen MJ, Wen L, Hayday AC, Craft J: Murine lupus in the absence of alpha beta T cells. J Immunol 1996, 156:4041-4049. Demonstrates a disease mechanism independent of α/β T cells, since even TCRα-/-mice develop several characteristics of autoimmunity, including autoantibody formation and immune complex deposits in the kidney.
28. Peng SL, Fatenejad S, Craft J: Induction of nonpathologic, humoral autoimmunity in lupus-prone mice by a class II-restricted, transgenic alpha beta T cell. Separation of autoantigen-specific and -nonspecific help. J Immunol 1996, 157:5225-5230. Shows that non-cognate help from αβ- T cells promotes generalized autoimmunity but that autoantigen-specific αβ T cells contribute to overt disease.
29. Takeda S, Rodewald H-R, Arakawa H, Bluethmann H, Shimizu T: MHC class II molecules are not required for survival of newly generated CD4+ T-cells but affect their long-term life span. Immunity 1996, 5:217-228.
30. Yung R, Powers D, Johnson K, Amento E, Carr D, Laing T, Yang J, Chang S, Hemati N, Richardson B: Mechanisms of drug-induced lupus II. T-cells overexpressing lymphocyte-function associated antigen 1 become autoreactive and cause a lupus-like disease in syngeneic mice. J Clin Invest 1996, 97:2866-2871.
31. Ma J, Xu J, Madaio MP, Peng Q, Zhang J, Grewal IS, Flavell RA, Craft J: Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses. J Immunol 1996, 157:417-426. Demonstrates that CD95-deficient B cells have an unusual ability to recruit help for autoantibody production.
32. Peng SL, McNiff JM, Madaio MP, Ma J, Owen MJ, Flavell RA, Hayday AC, Craft J: Alpha beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol 1997, 158:2464-2470. Demonstrates that CD95-deficient B cells have an unusual ability to recruit help for autoantibody production.
33. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
34. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW: Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment Immunity 1995, 3:521-530.
35. Suzuki H, Kündig TM, Furlonger C, Wakehan A, Timms E, Matsuyama T, Schmits R, Simard JJL, Ohashi P, Griesser H et al.: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 1995, 268:1472-1476.
36. Horak I, Löhler J, Ma A, Smith KA: Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995, 148:35-44.
37. Hünig T, Schimpl A. The IL-2 deficiency syndrome: a lethal disease caused by abnormal lymphocyte survival. In Cytokine Knockouts. Edited by Durum S, Muegge K. Totowa: Humana Press; 1997:in press.
38. Sadlack B, Löhler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I: Generalized autoimmune disease in interleukin-2 deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995, 25:3053-3059.
39. Krämer S, Schimpl A, Hünig T: Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J Exp Med 1995, 182:1769-1776.
40. Ehrhardt RO, Ludviksson BR, Gray B, Neurath M, Strober W: Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997, 158:566-573.
41. Kneitz B, Herrmann T, Yonehara S, Schimpl A: Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in IL-2 deficient mice. Bur J Immunol 1995, 25:2572-2577.
42. Lenardo MJ: Interleukin-2 programs mouse α/βT-lymphocytes for apoptosis. Nature 1991, 353:858-861.
43. Wang R, Rogers AM, Rush BJ, Russell JH: Induction of sensitivity to activation-induced death in primary CD4+ cells: a role for interleukin-2 in the negative regulation of responses by mature CD4+ T cells. Eur J Immunol 1996, 26:2263-2270. Shows that IL-2, but not IL-4, IL-7 or IL-15, provides the cytokine signal necessary for normal naïve mouse CD4+ T cells stimulated in vitro with ConA or plate bound anti CD3 to become sensitive to activation induced cell death.
44. Fournel S, Genestier L, Robinet E, Flacher M, Revillard JP: Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis. J Immunol 1996, 157:4309-4315.
45. Akbar AN, Borthwick NJ, Wickremasinghe RG, Panayoitidis P, Pilling D, Bofill M, Krajewski S, Reed JC, Salmon M: Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression. Eur J Immunol 1996, 26:294-299. This paper shows thai the ability to rescue activated human T cells from cell death following growth factor withdrawal is not a unique feature of IL-2, but is exhibited by all cytokines using the common γ-chain of the IL-2 receptor for signal transduction.
46. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, Talal N: SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol 1995, 155:3205-3212.
47. Tivol EA, Schweitzer AN, Sharpe AH: Costimulation and autoimmunity. Curr Opin Immunol 1996, 8:822-830.
48. Fuss IJ, Strober W, Dale JK, Fritz S, Pearlstein GR, Puck JM, Lenardo MJ, Straus SE: Characteristic T-helper 2 T-cell cytokine abnormalities in autoimmune lymphoproliferative syndrome: a syndrome marked by defective apoptosis and humoral autoimmunity. J Immunol 1997, 158:1912-1918.
49. Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, Strober W: A novel lymphoproliferative-autoimmune syndrome resembling murine lpr/gld disease. J Clin Invest 1992, 90:334-341.
50. Davignon J, Cohen PL, Eisenberg RA: Rapid T-cell receptor modulation accompanies lack of in vitro mitogenic responsiveness of double negative T-cells to anti-CD3 monoclonal antibody in MRL/Mp-lpr/lpr mice. J Immunol 1988, 141:1848-1854.
51. Giese T, Allison JP, Davidson WF: Functionally anergic lpr and gld 8220+ T-cell receptor (TCR) α/β+ double negative T-cells express CD28 and respond to costimulation with phorbol myristate acetate and antibodies to CD28 and the TCR. J Immunol 1993, 151:597-601.
52. Mori K, Kobayashi S, Inobe M, Yin WY, Tamakoshi M, Miyasaki T, Uede T: In vivo cytokine gene expression in various T-cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Autoimmunity 1994, 17:49-57.
53. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, Sato T, Reed JC, Green D, Swain SL: Unequal death in T helper cell (Th) 1 and Th2 effectors: TM, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997, 185:1837-1849. This paper draws attention to the differences between mouse Th1 and Th2 cells in becoming sensitive to CD95/C095L mediated activation induced cell death. The results suggest that in cases where the CD95/CD95L system fails the naturally more sensitive Th1 cells may unduly accumulate and thus contribute to autoimmune diseases associated with hyperactivity of Th1 cells.
54. Varadhachary AS, Perdow SN, Hu C, Ramanarayanan M, Salgame P: Differential ability of T-cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci USA 1997, 94:5778-5783. This paper shows that human Th1 clones, but not Th2 clones, become sensitive to activation induced cell death following CD3/T cell receptor ligation.
55. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M: Continuous administration of anti-Interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179:305-310.
56. Hagiwara E, Gourley MF, Lee S, Klinman DK: Disease severity in patients with systemic lupus erythematosous correlates with an increased ratio of Interleukin-10: Interferon gamma secreting cells in the peripheral blood. Arthritis Rheum 1996, 39:379-385.
57. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
58. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ: Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996, 184:429-440. Draws attention to a much neglected aspect of CD95-regulated homeosta-sis of the immune system, that is the control of granulocyte and monocyte numbers.
59. Um HD, Orenstein JM, Wahl SM: Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol 1996, 156:3469-3477. Draws attention to a much neglected aspect of CD95-regulated homeostasis of the immune system, that is the control of granulocyte and monocyte numbers.